Related Experiment Video
Updated: Jul 15, 2026
11:51
Expansion and Enrichment of Gamma-Delta (γδ) T Cells from Apheresed Human Product
Published on: September 22, 2021
Hepatosplenic gammadelta T-cell lymphoma: A case report
H J Meulenbeld1, W Spiering, P Nooijen
1Department of Internal Medicine, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands.
European Journal of Internal Medicine
|April 24, 2007
Summary
A rare and aggressive cancer, hepatosplenic gammadelta T-cell lymphoma, was diagnosed in a patient. Despite standard chemotherapy and alemtuzumab treatment, the patient experienced relapse, indicating limited therapeutic options.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Hepatosplenic gammadelta T-cell lymphoma is a rare and aggressive non-Hodgkin's lymphoma.
- This lymphoma primarily affects young men and is associated with a poor prognosis.
Purpose of the Study:
- To report a case of stage IV hepatosplenic gammadelta T-cell lymphoma.
- To highlight the challenges in treating this rare hematologic malignancy.
Main Methods:
- Clinical case presentation.
- Review of patient's medical history and treatment course.
Main Results:
- A 53-year-year-old male presented with weight loss, night sweats, and splenomegaly.
- Diagnosis of stage IV hepatosplenic gammadelta T-cell non-Hodgkin's lymphoma.
- Patient relapsed after CHOP chemotherapy and showed no response to alemtuzumab.
Conclusions:
- Hepatosplenic gammadelta T-cell lymphoma is highly aggressive and resistant to conventional therapies.
- Novel therapeutic strategies are urgently needed for this rare lymphoma subtype.
